PharmiWeb.com: Akebia Announces Publication of Phase 2b Data

September 10, 2016

Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced the publication of positive results from a Phase 2b study of vadadustat, a once-daily oral HIF stabilizer, in development for the treatment of anemia related to chronic kidney […]




AJMC.com: As Metformin Combinations Proliferate, Questions Arise About Value

September 10, 2016

Earlier this year, when the FDA granted initial approval to Jentadueto XR and a first-line indication to Invokamet, it gave fresh momentum to an entire category of medications: single pills that combine metformin with some other treatment for type 2 diabetes (T2D).  – See more at: http://www.ajmc.com/journals/evidence-based-diabetes-management/2016/september-2016/as-metformin-combinations-proliferate-questions-arise-about-value#sthash.jAAOQ94L.dpuf Read the full story at AJMC.com